ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,469.30
0.39%
Dow Jones
39,112.16
-0.76%
US Dollar vs MXN
18.1084
-0.10%
Brent Oil
84.665
0.57%
Bitcoin
61,631.35
-0.28%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Spyre Therapeutics Inc (SYRE)

  7. Spyre Therapeutics Inc (SYRE) Noticias

SYRE

Spyre Therapeutics (SYRE)

Spyre Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:SYRE
FechaHoraFuenteTítuloSímboloCompañía
18/06/202406:30PR Newswire (US)Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel DiseaseNASDAQ:SYRESpyre Therapeutics Inc
03/06/202416:23PR Newswire (US)Spyre Therapeutics Announces Grants of Inducement AwardsNASDAQ:SYRESpyre Therapeutics Inc
30/05/202415:33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SYRESpyre Therapeutics Inc
29/05/202407:30PR Newswire (US)Spyre Therapeutics to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:SYRESpyre Therapeutics Inc
16/05/202415:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRESpyre Therapeutics Inc
16/05/202415:05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SYRESpyre Therapeutics Inc
15/05/202406:30PR Newswire (US)Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of DirectorsNASDAQ:SYRESpyre Therapeutics Inc
09/05/202415:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SYRESpyre Therapeutics Inc
09/05/202415:02PR Newswire (US)Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:SYRESpyre Therapeutics Inc
18/03/202407:00PR Newswire (US)Spyre Therapeutics Announces $180 Million Private PlacementNASDAQ:SYRESpyre Therapeutics Inc
05/03/202416:15Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:SYRESpyre Therapeutics Inc
01/03/202405:14Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:SYRESpyre Therapeutics Inc
29/02/202416:06Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SYRESpyre Therapeutics Inc
29/02/202415:05PR Newswire (US)Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:SYRESpyre Therapeutics Inc
26/02/202406:30PR Newswire (US)Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care ConferenceNASDAQ:SYRESpyre Therapeutics Inc
14/02/202419:47Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SYRESpyre Therapeutics Inc
08/02/202406:30PR Newswire (US)Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis OrganisationNASDAQ:SYRESpyre Therapeutics Inc
05/02/202406:30PR Newswire (US)Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of DirectorsNASDAQ:SYRESpyre Therapeutics Inc
29/12/202316:00Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:SYRESpyre Therapeutics Inc
26/12/202320:56Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:SYRESpyre Therapeutics Inc
22/12/202315:32Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:SYRESpyre Therapeutics Inc
08/12/202315:07Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:SYRESpyre Therapeutics Inc
08/12/202315:06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SYRESpyre Therapeutics Inc
08/12/202315:03Edgar (US Regulatory)Form 3/A - Initial statement of beneficial ownership of securities: [Amend]NASDAQ:SYRESpyre Therapeutics Inc
01/12/202315:15Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SYRESpyre Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SYRE

Su Consulta Reciente

USI
USTECH100
US Tech 100
NASDAQ
TSLA
Tesla
NASDAQ
MSFT
Microsoft
NYSE
MCD
McDonalds
NASDAQ
GOOGL
Alphabet
NYSE
XOM
Exxon Mobil
COIN
ETHUSD
Ethereum
AMEX
SPY
SPDR S&P 500
NASDAQ
QQQ
Invesco QQQ Trust Series 1
AMEX
XLE
Energy Select Sector SPDR
COIN
SOLUSD
Solana
AMEX
XLF
Financial Select Sector
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
DIS
Walt Disney
USOTC
BASFY
BASF (QX)
USOTC
ADDYY
Adidas (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados